title: Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
abstract: Iron overload disorders involve excess accumulation of iron in body tissues as a result of hereditary and nonhereditary diseases. If left untreated, tissue iron deposition can result in organ damage. Treatment options such as phlebotomy, chelating agents, and erythrocytapheresis can prevent complications and target organ damage. Although phlebotomy is the gold standard for iron overload treatment in the setting of hereditary hemochromatosis, this procedure is usually not feasible for other iron overload conditions, especially those associated with anemia. With the introduction of newer, oral chelating agents, more options are available for patients refractory to or intolerant of parenteral chelating agents.
authors.affiliation: Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Penny
authors.initials: P
authors.lastname: Bring
authors.forename: Nilufar
authors.initials: N
authors.lastname: Partovi
authors.forename: Jo-Ann E
authors.initials: JA
authors.lastname: Ford
authors.forename: Eric M
authors.initials: EM
authors.lastname: Yoshida
mesh_terms: D001565:Benzoates / Q000627:therapeutic use; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000627:therapeutic use; D004032:Diet; D004359:Drug Therapy, Combination; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019190:Iron Overload / Q000235:genetics / Q000628:therapy*; D009154:Mutation; D018962:Phlebotomy; D011728:Pyridones / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D003676:Deferoxamine; D000077588:Deferasirox